MedTrace Logo

Alfentanil: Simultaneous Testing Pilot

NCT01008059 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2019-05-17

Study results available
· View outcomes & findings →

Summary

To evaluate two paradigms for simultaneous assessment of hepatic and intestinal CYP3A activity.

Conditions

  • Evaluate Two Paradigms for Simultaneous Assessment of Hepatic and Intestinal CYP3A

Interventions

DRUG

Alfentanil

No drug treatment before alfentanil

Sponsors & Collaborators

  • National Institute of General Medical Sciences (NIGMS)

    collaborator NIH

  • Washington University School of Medicine

    lead OTHER

Principal Investigators

  • Evan D Kharasch, MD, PhD · Washington University School of Medicine

Study Design

Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-10-31
Primary Completion
2016-09-30
Completion
2016-09-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01008059 on ClinicalTrials.gov